Retatrutide

Evidence: ★★★★☆ · Status: Not Approved

💡 Did you know? Retatrutide is a 'triple-G' drug — it mimics three metabolic hormones at once (GLP-1, GIP and glucagon), the next step beyond Ozempic-class drugs.

In plain English

Three metabolic switches in one molecule — two cut hunger, the third turns up calorie-burning. In the Phase 3 TRIUMPH-4 trial (Dec 2025) it produced 28.7% weight loss at 68 weeks — the largest ever for a drug. Not yet approved.

How it works

First-in-class triple agonist — GLP1R + GIPR + glucagon receptor (GCGR). Adding glucagon-receptor agonism raises energy expenditure and hepatic fat oxidation on top of the twin appetite pathways.

Molecular target & official sources

GCGR glucagon receptor (NCBI Gene) · GIPR (NCBI Gene) · GLP1R (NCBI Gene)

Watch out

GI effects; glucagon arm can nudge glucose/heart rate up. Long-term safety pending.

Bottom line

The likely next leader once approved. *Source: [Lilly TRIUMPH-4 release](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average).*

Helps with: Lose Fat

Stacks with

Shares a pathway — often paired with: Caffeine, Semaglutide (Ozempic / Wegovy / Rybelsus), Tirzepatide (Mounjaro / Zepbound), Liraglutide (Saxenda / Victoza).

Availability & where to buy

Not widely approved. Not approved for general sale in most markets (Singapore included). Grey-market only — dose, purity and legality uncertain.

How it works: the GPCR → cAMP pathway →

Compare Retatrutide

Common questions

Does Retatrutide actually work?

Human-evidence rating: 4 of 5. The likely next leader once approved. Source: Lilly TRIUMPH-4 release.

What are the risks or side effects of Retatrutide?

GI effects; glucagon arm can nudge glucose/heart rate up. Long-term safety pending.

Is Retatrutide legal or approved?

Regulatory status: Not Approved.